Q4 2025 Sera Prognostics Inc Earnings Call Transcript
Key Points
- Sera Prognostics Inc (SERA) made significant progress in 2025 by finalizing their prime publication, which showed a reduction in preterm births, enhancing their evidence portfolio.
- The company exceeded its state engagement goals, expanding discussions to 13 states and launching 2 live partner programs, with plans to expand to 15-17 states by the end of 2026.
- Sera Prognostics Inc (SERA) is making strides in advancing payer coverage and access, particularly through Medicaid and commercial payers, to support clinical adoption and reimbursement expansion.
- The company is on track to submit European dossiers for regulatory approval, aiming to unlock significant obstetric care opportunities in Europe.
- Sera Prognostics Inc (SERA) maintains a strong cash position with $95.8 million in cash equivalents, expected to fund operations through 2028, supporting their commercialization strategy.
- Revenue for the fourth quarter was only $10,000, down from $24,000 in the same period in 2024, indicating modest and fluctuating revenue at this early commercial stage.
- Operating expenses remain high at $9 million for the quarter, reflecting the ongoing costs associated with commercialization efforts.
- The net loss for the quarter was $7.9 million, slightly improved from $8.6 million in the previous year, but still significant.
- Despite progress, the adoption of Sera Prognostics Inc (SERA)'s tests is expected to be gradual, with revenue growth building slowly as partner programs mature.
- The company faces challenges in converting payer discussions into contracted coverage pathways, requiring ongoing efforts to demonstrate clinical and economic benefits.
Good afternoon ladies and gentlemen, and welcome to the Serra Prognostics fourth quarter 2025 financial results conference call.
At this time, all lines are in a listen-only mode. Following the presentation, we will conduct a question-and-answer session. If at any time during this call you require immediate assistance, please press 0 for the operator.
This call is being recorded on Wednesday, March 18, 2026. I would now like to turn the conference over to Jennifer Zibuda. Please go ahead.
Thank you, operator. Welcome to Cerra Prognostics 4th quarter and full fiscal year 2025 earnings conference call. At the close of market today, Cerra Prognostics released its financial results for the quarter ended December 31, 2025. Presenting for the company today will be Eugenia Lingard, President and CEO, Lee Anderson, Chief Commercial Officer, Dr. Tiffany Inglis, Chief Medical Officer, and Austin Ertz, our CFO.
During the call, we will review the financial results that we released
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
